Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad GeneticsSTU:MYD +0.30%57 Debt-to-Equity is 0.69 as of Jun. 2026, which is 214% above its 10-year median of 0.22. GuruFocus rates STU:MYD with a GF Score™ of 57/100 and a GF Value™ of €9.80 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 180 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 74.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Myriad Genetics's Debt-to-Equity or its related term are showing as below:
STU:MYD'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.22 Max: 0.69
Current: 0.69
During the past 13 years, the highest Debt-to-Equity Ratio of Myriad Genetics was 0.69. The lowest was 0.01. And the median was 0.22.
STU:MYD's Debt-to-Equity is ranked worse than 74.44% of 180
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.275
vs STU:MYD: 0.69
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Myriad Genetics Debt-to-Equity Related Terms
Myriad Genetics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a Debt-to-Equity of 0.69 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Myriad Genetics and its competitors. This is 214% above median its historical median of 0.22. Over the past decade, Myriad Genetics' Debt-to-Equity has ranged from 0.01 to 0.69. According to the industry distribution chart, Myriad Genetics ranks #134 out of 180 companies in the Medical Diagnostics & Research industry, placing it in the top 74.4%.
Is Myriad Genetics' Debt-to-Equity too high?
Myriad Genetics' current Debt-to-Equity of 0.69 is 214% above median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.69. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.28. Myriad Genetics' value of 0.69 is 150.9% above this industry median. Based on the distribution chart, Myriad Genetics ranks #134 out of 180 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Debt-to-Equity compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #134 out of 180 companies for Debt-to-Equity. This places Myriad Genetics in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Myriad Genetics' value of 0.69 is 150.9% above this benchmark. Historically, Myriad Genetics' own Debt-to-Equity has ranged from 0.01 to 0.69 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 0.28, Myriad Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.28, based on 180 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current Debt-to-Equity of 0.69 is 150.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Debt-to-Equity is 0.69, which is 214% above median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €9.80, compared to a current price of €2.70 — trading 72.4% below its estimated fair value. The current Debt-to-Equity is 0.69, which is 214% above median its 10-year median of 0.22 and 150.9% above the Medical Diagnostics & Research industry median of 0.28. Myriad Genetics' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Debt-to-Equity is 0.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €2.70 is trading 72.4% below its estimated GF Value™ of €9.80.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Debt-to-Equity: 0.69 (214% above median its 10-year median of 0.22)
GF Value™: €9.80 vs. price of €2.70 (72.4% below fair value)
Industry Position: 150.9% above the Medical Diagnostics & Research median (#134 of 180)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
57GF Score
Get the complete analysis for STU:MYD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
